These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 17698241)
1. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. Pectasides D; Samantas E; Fountzilas G; Briasoulis E; Kosmidis P; Skarlos D; Dimopoulos MA; Kalofonos HP; Economopoulos T; Syrigos K Lung Cancer; 2007 Dec; 58(3):355-61. PubMed ID: 17698241 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR; Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503 [TBL] [Abstract][Full Text] [Related]
6. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753 [TBL] [Abstract][Full Text] [Related]
9. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M; J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657 [TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V; Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877 [TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer. Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249 [TBL] [Abstract][Full Text] [Related]
14. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703 [TBL] [Abstract][Full Text] [Related]
16. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T; Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370 [TBL] [Abstract][Full Text] [Related]
17. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
18. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW; J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662 [TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]